December 31, 2002
Genta Incorporated To Present at JPMorgan H&Q Healthcare Conference
December 23, 2002
Genta and Avecia Sign Long-Term Manufacturing and Supply Agreement for Genasense(TM)
December 10, 2002
Early Clinical Results Suggest Genasense<sup>TM</sup> May Be Useful for Patients with Highly Resistant Multiple Myeloma
December 9, 2002
Two Studies Show Activity of Genasense<sup>TM</sup> In Acute Leukemia
December 9, 2002
Single-Agent Activity Lead Anticancer Compound, Genasense<sup>TM</sup>, Reported In Patients With Advanced Chronic Lymphocytic Leukemia
December 5, 2002
Annual Meeting Of The American Society Of Hematology Meeting Highlights Primacy Of The Genasense<sup>TM</sup> Target In Cancer Therapy
November 27, 2002
Leading Cancer Researcher, Jerome E. Groopman Appointed To Genta's Board Of Directors
November 26, 2002
Broad Genomic and Anticancer Activity Of Genta's CRE-Decoy Aptamer Presented At AARX/EORTC Symposium
November 22, 2002
Clincal Data Presented For Genasense<sup>TM</sup> Plus Chemotherapy For Newly Diagnosed Patients With Lung Cancer
November 7, 2002
Genta Announces 3rd Quarter Financial Results And Highlights
November 6, 2002
NCI Initiates Trials Of Genasense<sup>TM</sup> In Patients With Colorectal Cancer And Other Solid Tumors
October 31, 2002
Genta Incorporated Announces Conference Call to Discuss Third Quarter 2002 Earnings
October 29, 2002
NCI Initiates Clinical Trial Of Genasense<sup>TM</sup> With Rituxan® In Patients With Non-Hodgkins's Lymphoma
October 28, 2002
Genta Appoints Senior Pharmaceutical Industry Executive, William P. Keane, As Chief Financial Officer
October 8, 2002
Genta Reiterates Company Progress And Timelines For Genasense<sup>TM</sup>
October 3, 2002
Lymphoma & Myeloma Conference Highlights Importance Of Genasense<sup>TM</sup> Target In Cancer Therapy
October 1, 2002
Genta Incorporated To Present At UBS Warburg Life Sciences Conference
October 1, 2002
Genta Announces Initiation Of NCI/CALGB Trial Of Genasense<sup>TM</sup> Plus Gleevac® In Patients With Chronic Myeloid Leukemia
September 23, 2002
Genta Initiates Clinical Trial Of Genasense<sup>TM</sup> Plus Thalidomide In Patients With Multiple Myeloma
September 4, 2002
Genta Initiates Clinical Trial Of Genasense<sup>TM</sup> In Children With Cancer
August 8, 2002
Genta Announces Second Quarter Earnings Results And Highlights
July 31, 2002
Genta Announces Fourth Quarter and Year End 2001 Results and Highlights
June 18, 2002
Genta Incorporated Announces Audio WebCast Of 2002 Annual Shareholders Meeting
June 13, 2002
Genta Incorporated To Present At Thomas Weisel Partners Growth Forum
June 11, 2002
Genta Incorporated Announces Stock Repurchase Program
June 7, 2002
Genta Incorporated To Present At The BIO 2002 International Convention
June 3, 2002
Genta Receives $72 million in equity purchase from aventis pursuant to RECENT Collaboration FOR genasense<sup>TM</sup>
May 30, 2002
Genta Incorporated To Present At Needham & Co. Biotech Conference
May 28, 2002
Genta Appoints Bristol Myers Squibb Executive, Bharat Mehta, Ph.D., as vice-president of Manufacturing operations
May 21, 2002
Genta Initiates New Clinical Program For Gallium Nirtrate In Non-Hodgkin's Lymphoma
May 2, 2002
Genta Incorporated Announces First Quarter 2002 Results
April 29, 2002
Genta Incorporated And Aventis Announce Conference Call To Discuss Genasense Partnership
April 29, 2002
Genta Incorporated And Aventis Enter Worldwide Collaboration To Develop And Commercialize Genasense<sup>TM</sup>
April 15, 2002
Genta Appoints Douglas G. Watson, Former President And CEO Of Novartis Corporation, To Board Of Directors
April 11, 2002
Updated Survival Information Reported In Patients With Multiple Myeloma Treated With Genta's Gallium-Containing Drug
April 10, 2002
New Data at AACR Meeting Show Activity for Gentas Androgenics Drug in Prostate Cancer
April 9, 2002
Genasense<sup>TM</sup> Shown to be Effective Against Gleevec<sup>TM</sup>-Resistant Leukemia Cells
April 8, 2002
New Studies show Genasense<sup>TM</sup> Potentiates Anticancer Actions of Taxotere and Rituxan
March 25, 2002
Genta Appoints Pharmaceutical Industry Veteran, Jean OConnor, as Vice-President of Quality Assurance
March 1, 2002
Genta Incorporated to Present at Raymond James Institutional Investors Conference
February 21, 2002
Genta Announces Fourth Quarter and Year End 2001 Results and Highlights(2)
February 19, 2002
Genta Initiates Multicenter Trial with Genasense in Agressive Non-Hodgkin's Lymphoma
February 15, 2002
Genta CEO to Present in Roundtable, Plenary and Corporate Sessions at Bio CEO & Investor Conference
February 14, 2002
Genta to Announce Fourth-Quarter 2001 Financial Results
February 11, 2002
Genta Initiates Front-line Multicenter Trials with Genasense<sup>TM</sup> In Acute Leukemia and Small Cell Lung Cancer
January 25, 2002
Genta Incorporated to Present at U.S. Bancorp Piper Jaffray Health Care Conference
January 10, 2002
Genta Submits Investigational New Drug Application For Gallium Nitrate In Non-Hodgkin's Lymphoma
January 7, 2002
Genta Incorporated To Present At JP Morgan H&Q Healthcare Conference
